Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$281.49 -0.8%	$300.34	$253.30 ▼ $346.85	$151.13B	0.51	2.79 million shs	2.88 million shs
IBB iShares Biotechnology ETF	$126.97 +1.7%	$127.20	$107.43 ▼ $150.57	$5.55B	0.84	1.36 million shs	1.71 million shs
LEGN Legend Biotech	$33.42 -1.6%	$34.43	$29.27 ▼ $60.87	$6.14B	0.21	1.23 million shs	790,301 shs
REGN Regeneron Pharmaceuticals	$608.09 +3.1%	$628.85	$525.99 ▼ $1,211.20	$66.12B	0.44	743,344 shs	986,202 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-2.45%	+1.41%	-7.54%	-0.57%	+2.31%
IBB iShares Biotechnology ETF	-1.34%	+0.55%	+0.35%	-9.94%	-3.56%
LEGN Legend Biotech	-2.83%	-0.82%	+7.74%	-10.87%	-22.78%
REGN Regeneron Pharmaceuticals	-1.46%	-1.63%	-4.38%	-12.33%	-34.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.5357 of 5 stars	3.2	2.0	3.3	3.9	3.4	2.5	0.6
IBB iShares Biotechnology ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	2.6725 of 5 stars	3.5	3.0	0.0	0.0	3.0	1.7	0.6
REGN Regeneron Pharmaceuticals	4.8391 of 5 stars	4.4	5.0	1.7	2.3	2.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.43	Hold	$310.39	10.27% Upside
IBB iShares Biotechnology ETF	2.69	Moderate Buy	$126.84	-0.10% Downside
LEGN Legend Biotech	2.92	Moderate Buy	$78.82	135.88% Upside
REGN Regeneron Pharmaceuticals	2.88	Moderate Buy	$892.60	46.79% Upside

Current Analyst Ratings Breakdown

Latest LEGN, IBB, AMGN, and REGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/2/2025	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/2/2025	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
5/2/2025	AMGN Amgen	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$324.00 ➝ $320.00
5/1/2025	REGN Regeneron Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$940.00 ➝ $810.00
4/30/2025	REGN Regeneron Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$975.00 ➝ $940.00
4/30/2025	REGN Regeneron Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$917.00 ➝ $804.00
4/30/2025	REGN Regeneron Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$750.00 ➝ $700.00
4/30/2025	REGN Regeneron Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$1,051.00 ➝ $943.00
4/30/2025	REGN Regeneron Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$865.00 ➝ $800.00
4/30/2025	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$768.00 ➝ $633.00
4/25/2025	REGN Regeneron Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$759.00 ➝ $652.00

(Data available from 5/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.53	$28.21 per share	9.98	$10.93 per share	25.75
IBB iShares Biotechnology ETF	N/A	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	$627.24M	9.78	N/A	N/A	$6.88 per share	4.86
REGN Regeneron Pharmaceuticals	$14.09B	4.72	$39.93 per share	15.23	$268.50 per share	2.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$7.55	37.23	13.16	2.63	12.24%	176.32%	11.71%	N/A
IBB iShares Biotechnology ETF	N/A	N/A	25.09	∞	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	-$518.25M	-$0.48	N/A	N/A	N/A	-66.92%	-29.69%	-19.45%	5/13/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	15.80	15.99	2.34	31.07%	16.32%	12.76%	N/A

Latest LEGN, IBB, AMGN, and REGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	LEGN Legend Biotech	-$0.34	N/A	N/A	N/A	$190.83 million	N/A
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion
3/11/2025	Q4 2024	LEGN Legend Biotech	-$0.39	$0.07	+$0.46	$0.07	$179.00 million	$186.50 million
2/4/2025	Q4 2024	AMGN Amgen	$5.04	$5.31	+$0.27	$1.16	$8.87 billion	N/A
2/4/2025	Q4 2024	REGN Regeneron Pharmaceuticals	$11.21	$12.07	+$0.86	$8.06	$3.76 billion	$3.79 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.38%	+8.53%	126.09%	14 Years
IBB iShares Biotechnology ETF	$0.38	0.30%	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.58%	N/A	8.96%	N/A

Latest LEGN, IBB, AMGN, and REGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/4/2025	AMGN Amgen	quarterly	$2.38	3.05%	5/16/2025	5/16/2025	6/6/2025
5/1/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025
3/17/2025	IBB iShares Biotechnology ETF		$0.1212		3/18/2025	3/18/2025	3/21/2025
2/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.53%	2/20/2025	2/20/2025	3/20/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	9.62	1.26	0.95
IBB iShares Biotechnology ETF	N/A	N/A	N/A
LEGN Legend Biotech	0.27	4.98	4.90
REGN Regeneron Pharmaceuticals	0.09	4.73	3.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
IBB iShares Biotechnology ETF	62.45%
LEGN Legend Biotech	70.89%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.69%
IBB iShares Biotechnology ETF	N/A
LEGN Legend Biotech	0.02%
REGN Regeneron Pharmaceuticals	7.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	25,200	537.65 million	533.50 million	Optionable
IBB iShares Biotechnology ETF	N/A	43.75 million	N/A	Optionable
LEGN Legend Biotech	1,070	183.65 million	182.60 million	Optionable
REGN Regeneron Pharmaceuticals	11,900	109.33 million	101.15 million	Optionable

LEGN, IBB, AMGN, and REGN Headlines

Recent News About These Companies

UBS Group Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $633.00

May 2 at 11:04 AM | marketbeat.com

Schonfeld Strategic Advisors LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

May 2 at 6:31 AM | marketbeat.com

AQR Capital Management LLC Sells 18,449 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

May 2 at 6:10 AM | marketbeat.com

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’

May 1 at 4:04 PM | insidermonkey.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Quarterly Earnings Results, Misses Expectations By $0.61 EPS

May 1 at 12:44 PM | marketbeat.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Issues Quarterly Earnings Results, Misses Expectations By $0.61 EPS

May 1 at 12:23 PM | marketbeat.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down Following Weak Earnings

May 1 at 12:18 PM | marketbeat.com

Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination

May 1 at 9:30 AM | globenewswire.com

Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases

May 1 at 9:00 AM | globenewswire.com

PDT Partners LLC Grows Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

May 1 at 8:20 AM | marketbeat.com

California State Teachers Retirement System Has $119.59 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

May 1 at 7:14 AM | marketbeat.com

Northern Trust Corp Acquires 136,184 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

May 1 at 6:58 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Beacon Pointe Advisors LLC

May 1 at 6:44 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Public Employees Retirement Association of Colorado

May 1 at 6:32 AM | marketbeat.com

TD Waterhouse Canada Inc. Has $38,000 Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

May 1 at 4:35 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript

May 1 at 1:56 AM | seekingalpha.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2025 Earnings Call Transcript

May 1 at 1:56 AM | msn.com

Regeneron Shares Are Up Today: What's Going On?

April 30 at 4:36 PM | benzinga.com

The Manufacturers Life Insurance Company Purchases 18,366 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 30 at 7:50 AM | marketbeat.com

Regeneron Pharmaceuticals Inc (REGN) Q1 2025 Earnings Call Highlights: Strong Dupixent Sales ...

April 30 at 2:10 AM | gurufocus.com

Regeneron Reports Strong Q1 2025 Financial Results

April 30 at 12:33 AM | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Signs of a more buyer-friendly housing market emerge for the spring homebuying season
By The Associated Press | April 6, 2025
View Signs of a more buyer-friendly housing market emerge for the spring homebuying season
5 Highest-Rated Dividend Stocks According to MarketBeat
By Thomas Hughes | April 10, 2025
View 5 Highest-Rated Dividend Stocks According to MarketBeat
3 Stocks With Explosive Sales Growth and Strong Cash Flow
By Leo Miller | April 14, 2025
View 3 Stocks With Explosive Sales Growth and Strong Cash Flow

LEGN, IBB, AMGN, and REGN Company Descriptions

Amgen NASDAQ:AMGN

$281.39 -2.39 (-0.84%)

As of 03:23 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

iShares Biotechnology ETF NASDAQ:IBB

$127.00 +2.12 (+1.69%)

As of 03:23 PM Eastern

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Legend Biotech NASDAQ:LEGN

$33.42 -0.55 (-1.60%)

As of 03:23 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Regeneron Pharmaceuticals NASDAQ:REGN

$608.09 +18.09 (+3.07%)

As of 03:23 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time